


Table of Contents

Rosacea: From ORIGINS TO OUTCOMES

Proceedings From an
Expert Roundtable Meeting

July 2003
Chicago, Illinois



Supported by an independent grant from Galderma Laboratories, L.P.

Guest Editors:

John E. Wolf, Jr, MD, and James Q. Del Rosso, DO

Introduction

John E. Wolf, Jr, MD
Baylor College of Medicine, Houston, Texas

page 4

Rosacea as an Inflammatory Disorder: A Unifying Theory?

Larry E. Millikan, MD
Tulane University Health Sciences Center, New Orleans, Louisiana

page 5

**The Subtypes of Rosacea:
Implications for Treatment**

page 9

Richard B. Odom, MD
University of California, San Francisco

**Mechanism-Based Selection of
Pharmacologic Agents for Rosacea**

page 15

Alan Shalita, MD
State University of New York, Downstate Medical Center, Brooklyn

James Leyden, MD
University of Pennsylvania, Philadelphia

**The Role of Topical Metronidazole in
the Treatment of Rosacea**

page 19

John E. Wolf, Jr, MD
Baylor College of Medicine, Houston, Texas

**Evaluating the Role of Topical Therapies in
the Management of Rosacea: Focus on Combination
Sodium Sulfacetamide and Sulfur Formulations**

page 29

James Q. Del Rosso, DO
University of Nevada School of Medicine, Las Vegas

Roundtable Discussion: The Treatment of Rosacea

page 34

James Q. Del Rosso, DO
John E. Wolf, Jr, MD
James Leyden, MD
Larry E. Millikan, MD
Richard B. Odom, MD
Alan Shalita, MD